BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/14/2025 12:55:52 PM | Browse: 8 | Download: 34
 |
Received |
|
2024-11-18 09:02 |
|
Peer-Review Started |
|
2024-11-18 09:02 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-03-08 05:38 |
|
Revised |
|
2025-03-19 09:37 |
|
Second Decision |
|
2025-05-27 02:39 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-05-27 07:38 |
|
Articles in Press |
|
2025-05-27 07:38 |
|
Publication Fee Transferred |
|
2025-03-20 04:18 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-06-27 07:12 |
|
Publish the Manuscript Online |
|
2025-07-14 12:55 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Importance of landscape exploration and progress in molecular therapies and precision medicine for pancreatic ductal adenocarcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Maher Hendi, Bin Zhang, Yi-Ping Mou and Xiu-Jun Cai |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Xiu-Jun Cai, Chief Physician, FACS, FRCS, MD, PhD, President, Professor, Department of General Surgery, Zhejiang University School of Medicine, Sir Run Run Shaw Hospital, No. 3 Qingchun Road, Hangzhou 310016, Zhejiang Province, China. srrs_cxj@zju.edu.cn |
| Key Words |
Pancreatic ductal adenocarcinoma; Molecular subtypes; Transcriptomic; Microenvironment; Precision medicine; Therapeutic targets; Immunotherapy |
| Core Tip |
Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer death globally and is projected to be the second leading cause later. Kirsten rat sarcoma oncogene is a critical target for treatment regime evaluation in pancreatic ductal adenocarcinoma and proof of principle approaches have validated targeting in Kirsten rat sarcoma oncogene G12C. FOLFIRINOX and nab-paclitaxel gemcitabine are gold standard therapeutic in patients. The combinations were shown a survival benefit over previously standard gemcitabine monotherapy. Therapies targeting as well as immuno-therapies hold promise for the future but are currently not standard of care. |
| Publish Date |
2025-07-14 12:55 |
| Citation |
<p>Hendi M, Zhang B, Mou YP, Cai XJ. Importance of landscape exploration and progress in molecular therapies and precision medicine for pancreatic ductal adenocarcinoma. <i>World J Gastrointest Oncol</i> 2025; 17(7): 103337</p> |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i7/103337.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i7.103337 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
